Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to HFpEF failed to meet its primary endpoint (no improvement in 6-minute walk distance vs placebo) and did not achieve the key secondary endpoint (no improvement in KCCQ total symptom score). Management noted prespecified subgroups with a “substantial beneficial” effect in patients with greater disease burden, while safety was generally well tolerated with balanced serious adverse events across arms. Orion/Tenax plan to request a Type C Meeting with the FDA and parallel scientific consultation with the EMA to revise the ongoing registrational development strategy.

Analysis

This is a classic small-cap biotech de-risking failure where the equity reaction should be driven less by the subgroup narrative than by the change in capital structure odds. A full miss on both efficacy endpoints pushes the program from “late-stage asset” toward “regulatory negotiation asset,” which typically means lower probability-adjusted NPV, higher trial-design uncertainty, and a financing overhang within the next 1-3 months. For TENX, the key second-order effect is not just asset repricing but dilution risk if the company has to fund a revised registrational path before any external validation.

For ORN, the fundamental hit is much smaller because the exposure is option-like and likely immaterial relative to the core portfolio, but the stock can still trade mechanically with sentiment toward Nordic pharma / licensing optionality. If the market over-discounts ORN as though this were a core pipeline failure, that is a potential dislocation: the damage is to the royalty/milestone runway, not to the base earnings engine. The cleaner loser set is the broader orphan/PH-HFpEF development bucket, where investors may now demand stronger biomarker-to-clinical translation before paying for platform names.

The contrarian read is that the “biomarker/hemodynamic signal” may preserve some partnership value, but regulators usually care far more about symptom/function endpoints than mechanistic consistency. In other words, the market should not pay much for a rescue strategy unless the FDA explicitly blesses an enriched trial design; absent that, the timeline slips by 6-18 months and expected dilution increases. What would falsify the bearish thesis is a rapid FDA agreement on a prospectively enriched path plus credible non-dilutive funding, which would tighten the downside in TENX and could stabilize ORN.

Key Decisions for Investors

• Short TENX on any post-news bounce over the next 1-5 trading days; the risk/reward is favorable because the core valuation reset is likely still incomplete until FDA feedback and financing visibility arrive.
• Pair trade: long ORN / short TENX for 1-3 months if ORN sells off in sympathy; ORN’s exposure is more of a royalty-option haircut, while TENX faces financing and trial-redesign risk.
• Watch TENX for a capital raise or shelf filing within 30-60 days; if seen, maintain or add to the short because dilution becomes the dominant catalyst and can overwhelm any subgroup-driven narrative.
• Use XBI as a hedge only if biotech beta is the concern; relative to XBI, TENX should underperform materially over 1-3 months unless the FDA explicitly endorses an enriched-pathway trial.